Screener
Mineralys Therapeutics, Inc. MLYS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Cash.
The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001933414-26-000084
FAQ
- What is Mineralys Therapeutics, Inc.'s cash & equivalents?
- Mineralys Therapeutics, Inc. (MLYS) reported cash & equivalents of $1.15M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Mineralys Therapeutics, Inc.'s cash & equivalents decreased by 14.6% year-over-year, from $1.35M to $1.15M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s cash & equivalents?
- Over 4 years (2021 to 2025), Mineralys Therapeutics, Inc.'s cash & equivalents has grown at a -44.2% compound annual growth rate (CAGR), from $10.66M to $1.03M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Mineralys Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude